A Non-Randomized, Open-Label, Drug-Drug Interaction Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics and Safety of EDP-938 in Healthy Subjects
Latest Information Update: 21 Sep 2022
At a glance
- Drugs Fluconazole (Primary) ; Zelicapavir (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacokinetics
- Sponsors Enanta Pharmaceuticals
- 06 May 2021 New trial record